News | November 15, 2025
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
The observations are procedural in nature and will be responded to within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
The investment in land is Rs. 19.85 crore
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Fenebrutinib targets cells in the immune system known as B cells and microglia
Subscribe To Our Newsletter & Stay Updated
